Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients

Open access
Hilvo, Mika, Meikle, Peter J, Pedersen, Eva Ringdal, Tell, Grethe S, Dhar, Indu, Brenner, Hermann, Schöttker, Ben, Lääperi, Mitja, Kauhanen, Dimple, Koistinen, Kaisa M, Jylhä, Antti, Huynh, Kevin, Mellett, Natalie A, Tonkin, Andrew M, Sullivan, David R, Simes, John, Nestel, Paul, Koenig, Wolfgang, Rothenbacher, Dietrich, Nygård, Ottar, Laaksonen, Reijo · 2020 · European Heart Journal

Abstract

Aims: Distinct ceramide lipids have been shown to predict the risk for cardiovascular disease (CVD) events, especially cardiovascular death. As phospholipids have also been linked with CVD risk, we investigated whether the combination of ceramides with phosphatidylcholines (PCs) would be synergistic in the prediction of CVD events in patients with atherosclerotic coronary heart disease in three independent cohort studies. Methods and results: Ceramides and PCs were analysed using liquid chromatography–mass spectrometry (LC-MS) in three studies: WECAC (The Western Norway Coronary Angiography Cohort) (N = 3789), LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) trial (N = 5991), and KAROLA (Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung) (N = 1023). A simple risk score, based on the ceramides and PCs showing the best prognostic features, was developed in the WECAC study and validated in the two other cohorts. This score was highly significant in predicting CVD mortality [multiadjusted hazard ratios (HRs; 95% confidence interval) per standard deviation were 1.44 (1.28–1.63) in WECAC, 1.47 (1.34–1.61) in the LIPID trial, and 1.69 (1.31–2.17) in KAROLA]. In addition, a combination of the risk score with high-sensitivity troponin T increased the HRs to 1.63 (1.44–1.85) and 2.04 (1.57–2.64) in WECAC and KAROLA cohorts, respectively. The C-statistics in WECAC for the risk score combined with sex and age was 0.76 for CVD death. The ceramide-phospholipid risk score showed comparable and synergistic predictive performance with previously published CVD risk models for secondary prevention. Conclusion: A simple ceramide- and phospholipid-based risk score can efficiently predict residual CVD event risk in patients with coronary artery disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehz387

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 305

Metadata

Authors
Hilvo, M., Meikle, P. J., Pedersen, E. R., Tell, G. S., Dhar, I., Brenner, H., Schöttker, B., Lääperi, M., Kauhanen, D., Koistinen, K. M., Jylhä, A., Huynh, K., Mellett, N. A., Tonkin, A. M., Sullivan, D. R., Simes, J., Nestel, P., Koenig, W., Rothenbacher, D., Nygård, O., & Laaksonen, R.
Venue
European Heart Journal
Published
2019-06-18
Volume
41
Issue
3
Pages
371-380
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2949868611
Cited by
305
References
20
FWCI
28.09
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. https://app.cochat.ai/papers/10.1093/eurheartj/ehz387
The paper
Hilvo, M., Meikle, P. J., Pedersen, E. R., Tell, G. S., Dhar, I., Brenner, H., Schöttker, B., Lääperi, M., Kauhanen, D., Koistinen, K. M., Jylhä, A., Huynh, K., Mellett, N. A., Tonkin, A. M., Sullivan, D. R., Simes, J., Nestel, P., Koenig, W., Rothenbacher, D., . . . Laaksonen, R. (2020). Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz387

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.